Successful hepatitis C virus (HCV) treatment is associated with a reduced likelihood of fatigue, aidsmap reports. This may be because the liver inflammation and fibrosis (scarring) related to chronic hep C infection contributes to fatigue symptoms.
Researchers from the FAT-HEP study gave questionnaires about fatigue to 56 people with hep C seen in a clinic in Denmark. Findings were presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) in Oslo.
Thirty percent of those in the study group were currently using substances, 54 percent had done so in the past and 36 percent were taking opiate substitution therapy (OST) for addiction treatment. Sixty-eight percent of the total study group reported clinically significant fatigue.
The researchers did not find a statistically significant connection between fatigue and current or past substance use or taking OST, meaning that any apparent connection could have been the result of chance. (With a larger participant sample, perhaps such a connection would have been statistically significant.)
The study authors did find a significant association between various markers of liver disease severity. Having an alanine aminotransferase (AST, a liver enzyme) level greater than 30 international units per milliliter for men and 19 IU per ml for women was associated with a 5.3-fold increased likelihood of having fatigue. A FibroScan test result indicating that individuals likely had advanced fibrosis or cirrhosis was associated with a 5.8-fold increased likelihood of having fatigue.
Curing hep C, on the other hand, was associated with an 80 percent reduced likelihood of having fatigue.
The researchers concluded that past or present substance abuse or the use of OST do not on their own explain fatigue symptoms among people with hep C. Liver inflammation and fibrosis (scarring) of the organ may contribute to such symptoms.
To read the aidsmap article, click here.
To read the conference abstract, click here.